PATENT CLAIM ANALYSIS

Application Number: 16074429
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "093210"]

Abstract:
The invention provides a cellular immunotherapy therapy product comprising CAR T cells that are enriched in CD8+ cells. Also provided are methods for making and using the product.

Claim (Index 32):
A method for treating myeloma in an individual, the method comprising administering to the individual a product comprising a plurality of T cells, wherein:\n at least 10% of the T cells comprise a synthetic mRNA that encodes a chimeric antigen receptor protein; at least 80 percent of the T cells are CD8+ cells; at least some of the CD8+ cells express the chimeric antigen receptor protein; and the chimeric antigen receptor protein comprises an antigen recognition moiety that binds to BCMA.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 95.0
- Lexical Diversity: 1.15385
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14389677', '15965739', '15965738', '14805193', '16050754']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7223535473099494
- 35 USC 102 Novelty (BERT): 0.5280949231251059
- Combined Prediction Score: 0.702927684891465
- Mean Citation Score: 334.43033
- Max Citation Score: 346.75323
- Similarity Product: 252.2248496152997

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test